Hexarelin (also called Examorelin) is a synthetic hexapeptide growth-hormone secretagogue. It acts at the ghrelin receptor to stimulate the pituitary release of growth hormone and belongs to the GHRP family of peptides.

What does research suggest about Hexarelin?

Preclinical and animal studies report that Hexarelin stimulates growth-hormone release and shows cardiovascular effects. Human evidence is limited to a pharmacological study history, and it is not a validated or approved therapy.

Is Hexarelin approved or legal?

Hexarelin is not an approved medicine for general use and holds research-chemical status. Its legal standing varies by jurisdiction, and it is not authorized for human therapeutic use.

Hexarelin carries real hormonal risks and is not a validated therapy. Because it affects the growth-hormone axis and shows effects on prolactin and cortisol, its long-term safety is not well characterized, particularly for unregulated research-market material.

What are the reported side effects of Hexarelin?

Reported effects include water retention and changes in prolactin and cortisol. Desensitization, or tolerance, where the growth-hormone response diminishes with repeated exposure, is also frequently discussed.

How is Hexarelin different from other GH secretagogues?

Hexarelin is regarded as one of the more potent GHRP-family peptides and, unlike GHRH analogues such as CJC-1295, it works through the ghrelin receptor. It is also noted for cardiac-related effects reported in preclinical research.

How does Hexarelin differ from other growth-hormone secretagogues like GHRP-6 or CJC-1295?

Hexarelin is a hexapeptide in the GHRP family, so it is closest in kind to GHRP-6 and GHRP-2 — all act on the ghrelin/GH-secretagogue receptor to trigger a pulse of growth hormone. That mechanism differs from CJC-1295, which is a GHRH analogue working through a separate receptor. A frequently discussed distinction is that hexarelin has been reported to have direct cardiovascular effects in preclinical work and a notable tendency toward desensitisation. These are points of scientific discussion, not endorsements of use.

Why is Hexarelin's tendency toward tolerance a recurring topic?

A theme throughout the pharmacological literature is that the growth-hormone response to hexarelin can diminish with repeated exposure — often described as desensitisation or tolerance. This is one reason it never became a straightforward therapeutic tool and is a common discussion point when people compare it with other secretagogues. It is background context on the compound's biology, not guidance on any pattern of use.

Is Hexarelin the same thing as examorelin?

Yes — examorelin is the international nonproprietary (generic) name for hexarelin, so the two terms refer to the same synthetic hexapeptide. Seeing both names can cause confusion when reading older or more technical sources, but they are not different compounds.

Where can I buy Hexarelin and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Growth Hormone Secretagogue

Buy Hexarelin – Vendors, Prices, Testing and Evidence

Buy Hexarelin

Also known as: Examorelin

Evidence grade C — Early / PreclinicalRisk flag

Short answer

A potent growth-hormone-releasing peptide with limited human evidence and hormonal risks.

Where can you buy Hexarelin?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

Hexarelin is a synthetic hexapeptide growth-hormone secretagogue.

What is not established?

Limited pharmacological study history; not an approved therapy.

Safety

Hormonal effects and potential desensitisation; not a validated therapy.

Regulatory status

Not an approved medicine for general use. Research chemical status.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy Hexarelin: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	Hexarelin research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

Hexarelin research product

Code PEPTIDES10 −10% · discount code details

What is it?

Hexarelin is a synthetic hexapeptide growth-hormone secretagogue.

Research and evidence

Hexarelin, also known as Examorelin, is a synthetic hexapeptide classified as a growth-hormone secretagogue (GHS). Structurally related to the GHRP family, it acts primarily at the ghrelin receptor (GHS-R1a) to stimulate the pituitary release of growth hormone (GH). Researchers describe it as one of the more potent GH-releasing peptides studied, and it has drawn interest not only for its effect on the GH axis but also for cardiac and cardiovascular effects reported in preclinical work. Importantly, Hexarelin is not an approved medicine for general use; it circulates as a research chemical and carries meaningful hormonal risks.

The scientific rationale for studying Hexarelin centers on its ability to trigger GH secretion through a ghrelin-receptor-mediated pathway that is distinct from GHRH. Animal studies have documented both GH-release and cardiovascular effects, and some findings point to receptor interactions beyond the classic GH pathway. Human data, however, remain limited: Hexarelin has a pharmacological study history but has not been validated or approved as a therapy. A recurring theme in the literature and in community discussion is desensitization, or tolerance, where repeated exposure appears to blunt the GH response over time. This makes Hexarelin a subject of mechanistic curiosity rather than an established clinical tool.

From an evidence and safety standpoint, the honest picture is cautious. Hexarelin's hormonal activity is not confined to GH; reports describe effects on prolactin and cortisol, along with water retention as a commonly noted side effect. Because it manipulates the endocrine system, any effect on the GH axis warrants careful scrutiny, and the long-term profile of research-market material is not well characterized. This page is an educational reference summarizing what is known and where evidence is thin — distinguishing preclinical and animal findings from the sparse human data — and is not medical advice, a protocol, or an endorsement of use.

Evidence grade: C

Limited pharmacological study history; not an approved therapy. GH-release and cardiovascular effects reported preclinically.

Human evidence

Limited pharmacological study history; not an approved therapy.

Animal and preclinical evidence

GH-release and cardiovascular effects reported preclinically.

Proposed mechanisms

Ghrelin-receptor-mediated GH release
Discussed cardiac effects

Safety concerns and known side effects

Hormonal effects and potential desensitisation; not a validated therapy.

Water retention
Prolactin/cortisol effects reported

Regulatory status

Not an approved medicine for general use. Research chemical status.

Hexarelin research timeline

Early 1990s
Hexarelin (also called examorelin) is developed as a synthetic hexapeptide growth-hormone secretagogue, part of a wave of GHRP-family compounds designed after the first growth-hormone-releasing peptides.
1990s
Preclinical and early pharmacological studies characterize its potent, ghrelin-receptor-mediated growth-hormone release, and researchers begin reporting cardiovascular effects independent of GH.
Late 1990s
Small human pharmacological studies explore its GH-releasing potency and note that repeated exposure can blunt the response (desensitisation), a recurring theme in the literature.
2000s
Interest as a therapeutic candidate fades; hexarelin is never brought to market as an approved medicine, and attention shifts to longer-acting or orally available secretagogues.
2000s onward
Growth-hormone secretagogues including hexarelin are placed on the World Anti-Doping Agency prohibited list, banning them in competitive sport.
2010s–2020s
Hexarelin circulates in the research-chemical market with no new approval; its human evidence base remains limited and it is not a validated therapy.

Frequently asked questions about Hexarelin

What is Hexarelin?: Hexarelin (also called Examorelin) is a synthetic hexapeptide growth-hormone secretagogue. It acts at the ghrelin receptor to stimulate the pituitary release of growth hormone and belongs to the GHRP family of peptides.
What does research suggest about Hexarelin?: Preclinical and animal studies report that Hexarelin stimulates growth-hormone release and shows cardiovascular effects. Human evidence is limited to a pharmacological study history, and it is not a validated or approved therapy.
Is Hexarelin approved or legal?: Hexarelin is not an approved medicine for general use and holds research-chemical status. Its legal standing varies by jurisdiction, and it is not authorized for human therapeutic use.
Is Hexarelin safe?: Hexarelin carries real hormonal risks and is not a validated therapy. Because it affects the growth-hormone axis and shows effects on prolactin and cortisol, its long-term safety is not well characterized, particularly for unregulated research-market material.
What are the reported side effects of Hexarelin?: Reported effects include water retention and changes in prolactin and cortisol. Desensitization, or tolerance, where the growth-hormone response diminishes with repeated exposure, is also frequently discussed.
How is Hexarelin different from other GH secretagogues?: Hexarelin is regarded as one of the more potent GHRP-family peptides and, unlike GHRH analogues such as CJC-1295, it works through the ghrelin receptor. It is also noted for cardiac-related effects reported in preclinical research.
How does Hexarelin differ from other growth-hormone secretagogues like GHRP-6 or CJC-1295?: Hexarelin is a hexapeptide in the GHRP family, so it is closest in kind to GHRP-6 and GHRP-2 — all act on the ghrelin/GH-secretagogue receptor to trigger a pulse of growth hormone. That mechanism differs from CJC-1295, which is a GHRH analogue working through a separate receptor. A frequently discussed distinction is that hexarelin has been reported to have direct cardiovascular effects in preclinical work and a notable tendency toward desensitisation. These are points of scientific discussion, not endorsements of use.
Why is Hexarelin's tendency toward tolerance a recurring topic?: A theme throughout the pharmacological literature is that the growth-hormone response to hexarelin can diminish with repeated exposure — often described as desensitisation or tolerance. This is one reason it never became a straightforward therapeutic tool and is a common discussion point when people compare it with other secretagogues. It is background context on the compound's biology, not guidance on any pattern of use.
Is Hexarelin the same thing as examorelin?: Yes — examorelin is the international nonproprietary (generic) name for hexarelin, so the two terms refer to the same synthetic hexapeptide. Seeing both names can cause confusion when reading older or more technical sources, but they are not different compounds.
Where can I buy Hexarelin and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

GH axisTolerance

Compare Hexarelin

Hexarelin vs GHRP-2

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10